Last updated: June 18, 2026
Boehringer Ingelheim v. Alkem Laboratories 1:18-cv-01738: Litigation Summary, Claims at Issue, and Patent/Regulatory Impact
Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) sued Alkem Laboratories Ltd. in the District of New Jersey over patent infringement tied to an FDA-regulated product associated with Boehringer Ingelheim’s portfolio. The case number is 1:18-cv-01738. Public docket-level detail is required to produce an accurate claims-at-issue and exclusivity/Paragraph IV analysis, including which patents were asserted, which Orange Book listed drug and NDA/ANDA were implicated, what allegations were pled (infringement theories), and whether the litigation ended in a settlement or other disposition.
No such case-specific docket or pleading content is available in the provided record here; therefore, a complete, accurate litigation summary and analysis cannot be generated.
What patents were asserted in Boehringer Ingelheim v. Alkem 1:18-cv-01738?
No complete answer is possible without the complaint and asserted-patent list (or docket entries identifying the patents).
Which BIPI patents are commonly asserted in related BIPI v. generic cases?
A valid list cannot be generated for this case without the specific asserted documents from 1:18-cv-01738.
What claim types were typically pled in this matter?
Infringement theory (direct, indirect, inducement, willful) depends on the asserted patents and the accused product description in the pleadings. Those details are not present.
When was the lawsuit filed, and what were the procedural milestones in 1:18-cv-01738?
A chronology requires docket entries. Without the docket timeline, accuracy cannot be maintained.
Filing and service timeline
Cannot be stated from the provided information.
Motions and orders (TRO, preliminary injunction, claim construction)
Cannot be stated from the provided information.
Case disposition
Cannot be stated from the provided information.
What claims did Alkem dispute in Boehringer Ingelheim v. Alkem Laboratories Ltd.?
A meaningful infringement and invalidity dispute summary must cite the defenses raised (non-infringement, invalidity grounds, unenforceability, lack of jurisdiction, or forfeiture). Those specifics are not provided.
Invalidity contentions (anticipation/obviousness/indefiniteness)
Cannot be enumerated without the invalidity pleadings and the asserted claims.
Non-infringement contentions tied to the accused product
Cannot be assessed without the product description and infringement claim chart.
How does 1:18-cv-01738 affect FDA exclusivity and generic entry risk?
An exclusivity and entry-risk analysis requires: (1) the specific NDA/ANDA and (2) whether the filing was tied to a Paragraph IV certification under 21 U.S.C. § 355(j)(2)(A) or § 355(c)(3) (as applicable). Those identifiers are not available here.
What Orange Book listing is implicated?
Not determinable from the provided record.
What is the generic launch exposure window?
Not determinable without patent expiration dates and any settlement-triggered launch dates.
Was this litigation settled, and what were the terms for launch or licensing?
Settlement status and terms depend on docket entries and settlement agreement text or docket summaries. None are provided.
Did Alkem enter under a covenant not to sue?
Cannot be determined.
Did the case end in dismissal or consent judgment?
Cannot be determined.
What settlement agreements or consent judgments typically govern similar BIPI vs. generic cases?
A generalized template cannot replace case-specific terms. This section cannot be completed accurately for 1:18-cv-01738.
Does this case involve Paragraph IV challenges, and what does that imply for patent strength?
To map Paragraph IV implications, the record must identify the ANDA/NDA and the asserted patent(s) certified against. That information is not present, so the “strength” inference cannot be supported.
Key Takeaways
- Case identifier confirmed: Boehringer Ingelheim Pharmaceuticals Inc. v. Alkem Laboratories Ltd., 1:18-cv-01738.
- Case-specific litigation summary and analysis cannot be completed without asserted-patent identification, docket/procedural disposition, and the NDA/ANDA and Orange Book context.
- No accurate conclusions on patent validity, infringement theories, settlement timing, or generic entry risk can be stated from the provided information.
FAQs
- What patents did Boehringer Ingelheim assert against Alkem in 1:18-cv-01738?
- Did Alkem file an ANDA with a Paragraph IV certification tied to this case?
- What court orders (e.g., claim construction, injunction rulings) shaped the outcome in 1:18-cv-01738?
- Did the parties reach a settlement, and did it include a negotiated launch date or payment terms?
- What is the Orange Book status for the drug implicated by Boehringer Ingelheim Pharmaceuticals Inc. in this action?
References
- Public docket source for 1:18-cv-01738 is required to cite pleadings, orders, and dispositive documents.
